1 / 12

SILEN-C3 trial

Treatment for 12 or 24 weeks with BI201335 combined with peg-interferon alfa-2a and ribavirin (PR) in treatment-naïve patients with chronic genotype-1 HCV infection: Results of the SILEN-C3 trial. SILEN-C3 trial . Main inclusion criteria. Baseline characteristics. Virologic response.

obert
Télécharger la présentation

SILEN-C3 trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Treatment for 12 or 24 weeks with BI201335 combined with peg-interferon alfa-2a and ribavirin (PR) in treatment-naïve patients with chronic genotype-1 HCV infection: Results of the SILEN-C3 trial

  2. SILEN-C3 trial

  3. Main inclusion criteria

  4. Baseline characteristics

  5. Virologic response

  6. Treatment outcome

  7. Time to undetectable HCV RNAcorrelated with SVR

  8. Adverse events: overall summary

  9. Most common adverse events (>15% in any group)

  10. Summary

  11. Acknowledgements

More Related